Rare diseaseNDM Pharma provides POC for NMD670Latest NewsResearchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis. Read more 22 March 2024 https://european-biotechnology.com/wp-content/uploads/2024/04/NDM_Pharma.png 1250 2500 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-03-22 06:18:002024-06-13 14:05:20NDM Pharma provides POC for NMD670